Cancer Research and Treatment

Original Articles

A Prospective, Single-Cohort, Open, Multi-center, Observational Study of Sublingual Fentanyl for Breakthrough Cancer Pain: Effectiveness, Safety, and Tolerability in Korean Cancer Patients: Youn Seon Choi, Su-Jin Koh, Woo Kyun Bae, Se Hyung Kim, Seong Hoon Shin, So Yeon Oh, Sang Byung Bae, Yaewon Yang, Eun-Kee Song, Yoon Young Cho, Pyung Bok Lee, Ho-Suk Oh, MinYoung Lee, Jin Seok Ahn; Received June 13, 2024 Accepted December 24, 2024 Published online December 26, 2024; DOI: https://doi.org/10.4143/crt.2024.557 [Epub ahead of print]

Abstract PDF PubReader ePub: Purpose
Fentanyl, a highly lipophilic opioid, was developed as a sublingual fentanyl tablet (SFT) for the management of breakthrough cancer pain (BTcP), and its efficacy and safety were confirmed in a randomized, controlled study. We investigated the effectiveness and safety of SFT administered to alleviate BTcP in a real-world setting.
Materials and Methods
In this prospective, open, single-cohort study, conducted in 13 referral hospitals in South Korea, opioid-tolerant cancer patients receiving around-the-clock opioids for persistent cancer pain were enrolled if the individual had BTcP ≥ 1 episode/day during the preceding week. The primary outcome was the SFT titration success rate.
Results
Among 113 patients evaluated for effectiveness, 103 patients (91.2%) had a successful titration of SFT, with an effective dose range between 100 μg and 400 μg. The most frequent dose was 100 μg, administered to 65.0%, 72.1%, and 81.8% of the patients at week 1, 4, and 12, respectively. The proportion of patients achieving the personalized pain goal assessed in the first week was 75.2%. The mean change in pain intensity measured with a numeric rating scale at 30 and 60 minutes after taking SFT was –2.57 and –3.62, respectively (p < 0.001 for both). The incidence rate of adverse events related to SFT among 133 patients included for safety evaluation was 9.0% (12/133), which included vomiting (3.0%), nausea (2.3%), and headache (1.5%).
Conclusion
In a real-world setting, SFT provides rapid and effective analgesia in BTcP, even at the lowest dose (100 μg), and the safety profile was acceptable.

701 View
77 Download

Impact of Mucin Proportion in the Pretreatment MRI on the Outcomes of Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy: Eunji Kim, Kyubo Kim, Se Hyung Kim, Sae-Won Han, Tae-You Kim, Seung-Yong Jeong, Kyu Joo Park, Jaemoon Koh, Gyeong Hoon Kang, Eui Kyu Chie; Cancer Res Treat. 2019;51(3):1188-1197. Published online December 20, 2018; DOI: https://doi.org/10.4143/crt.2018.434

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to evaluate treatment response to neoadjuvant chemoradiotherapy (CRT) with regard to mucin status in pathology and pretreatment magnetic resonance imaging (MRI) in locally advanced rectal cancer.
Materials and Methods
Between 2003 and 2011, 306 patients with locally advanced rectal cancer received neoadjuvant CRT followed by surgery, and mucinous adenocarcinoma (MAC) was found in 27 (8.8%). All MAC patients had MRI before and after CRT and mucin proportion at MRI was measured. Therapeutic response was assessed by pathology after total mesorectal excision. To determine the optimal cut-off for mucin proportion in predicting good CRT response (near total or total regression) and negative circumferential resection margin (CRM), the receiver-operating characteristic analysis was performed.
Results
After neoadjuvant CRT, overall downstaging occurred in 44.4% of MAC and 72.4% of non-MAC (p=0.001), and positive CRM (≤1 mm) was observed more frequently in MAC (p<0.001). The optimal threshold for treatment response was 30% for mucin proportion, and there are nine with low mucin proportion (<30%) and 18 with high mucin proportion (≥30%) in pretreatment MRI. Negative CRM and tumor downstaging occurred more common in patients with mucin <30%, although statistically insignificant (p=0.071 and p=0.072, respectively). Regarding oncologic outcomes, lower mucin proportion in pretreatment MRI was associated with better disease-free and overall survival in MAC group (p=0.092 and 0.056, respectively), but the difference did not reach statistical significance.
Conclusion
Poor treatment outcome with neoadjuvant CRT was observed in patients with MAC, especially those with high mucin proportion at pretreatment MRI.

Citations

Citations to this article as recorded by

Mucinous histology is a negative predictor of neoadjuvant chemoradiotherapy for locally advanced rectal adenocarcinoma
Xiangwen Tan, Yiwei Zhang, Xiaofeng Wu, Qing Fang, Yunhua Xu, Shuxiang Li, Jinyi Yuan, Xiuda Peng, Kai Fu, Shuai Xiao
BMC Gastroenterology.2024;[Epub] CrossRef
Incomplete Resection Is Twice as Likely in Locally Advanced Mucinous Compared to Nonmucinous Rectal Adenocarcinoma: A National Propensity‐Matched Analysis
Leah E. Hendrick, Samer Naffouje, Iman Imanirad, Allan Lima Pereira, Tiago Biachi, Julian Sanchez, Sophie Dessureault, Amalia Stefanou, Sean P. Dineen, Seth Felder
Journal of Surgical Oncology.2024;[Epub] CrossRef
Accelerated T2W Imaging with Deep Learning Reconstruction in Staging Rectal Cancer: A Preliminary Study
Lan Zhu, Bowen Shi, Bei Ding, Yihan Xia, Kangning Wang, Weiming Feng, Jiankun Dai, Tianyong Xu, Baisong Wang, Fei Yuan, Hailin Shen, Haipeng Dong, Huan Zhang
Journal of Imaging Informatics in Medicine.2024;[Epub] CrossRef
Mucinous rectal cancers: clinical features and prognosis in a population-based cohort
Malin Enblad, Klara Hammarström, Joakim Folkesson, Israa Imam, Milan Golubovik, Bengt Glimelius
BJS Open.2022;[Epub] CrossRef
Mucin-Containing Rectal Cancer: A Review of Unique Imaging, Pathology, and Therapeutic Response Features
David D. Childs, Caio Max Sao Pedro Rocha Lima, Yi Zhou
Seminars in Roentgenology.2021; 56(2): 186. CrossRef
Advances in radiological staging of colorectal cancer
R.J. Goiffon, A. O'Shea, M.G. Harisinghani
Clinical Radiology.2021; 76(12): 879. CrossRef
A Comprehensive Evaluation of Associations Between Routinely Collected Staging Information and The Response to (Chemo)Radiotherapy in Rectal Cancer
Klara Hammarström, Israa Imam, Artur Mezheyeuski, Joakim Ekström, Tobias Sjöblom, Bengt Glimelius
Cancers.2020; 13(1): 16. CrossRef

8,643 View
174 Download
7 Web of Science
7 Crossref

Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX: Mi-Jung Kim, Sae-Won Han, Dae-Won Lee, Yongjun Cha, Kyung-Hun Lee, Tae-Yong Kim, Do-Youn Oh, Se Hyung Kim, Seock-Ah Im, Yung-Jue Bang, Tae-You Kim; Cancer Res Treat. 2016;48(3):990-997. Published online January 14, 2016; DOI: https://doi.org/10.4143/crt.2015.296

Abstract PDF Supplementary Material PubReader ePub

Purpose
Splenomegaly is a clinical surrogate of oxaliplatin-induced sinusoidal obstruction syndrome (SOS). We investigated development of splenomegaly and its association with treatment outcome and genetic polymorphisms following adjuvant 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in colorectal cancer (CRC) patients.
Materials and Methods
Splenomegaly was determined by spleen volumetry using computed tomography images obtained before initiation of chemotherapy and after completion of adjuvant FOLFOX in CRC patients. Ten genetic polymorphisms in 4 SOS-related genes (VEGFA, MMP9, NOS3, and GSTP1) were analyzed using DNA from peripheral blood mononuclear cells.
Results
Of 124 patients included, increase in spleen size was observed in 109 (87.9%). Median change was 31% (range, –42% to 168%). Patients with splenomegaly had more severe thrombocytopenia compared to patients without splenomegaly during the chemotherapy period (p < 0.0001). The cumulative dose of oxaliplatin and the lowest platelet count during the chemotherapy period were clinical factors associated with splenomegaly. However, no significant associations were found between genetic polymorphisms and development of splenomegaly. Disease-free survival was similar regardless of the development of splenomegaly.
Conclusion
Splenomegaly was frequently observed in patients receiving adjuvant FOLFOX and resulted in more severe thrombocytopenia but did not influence treatment outcome. Examined genetic polymorphisms did not predict development of splenomegaly.

Citations

Citations to this article as recorded by

Association of VEGF promoter polymorphisms with gastrointestinal tract cancer risk and therapy response: a systematic review
Deepanshi Mahajan, Vasudha Sambyal, Kamlesh Guleria
Egyptian Journal of Medical Human Genetics.2025;[Epub] CrossRef
Association of Vascular Endothelial Growth Factor Gene Polymorphisms with Esophageal Squamous Cell Cancer Risk in North-West Indians: A Case–Control Study
Deepanshi Mahajan, Vasudha Sambyal, Meena Sudan, Manjit Singh Uppal, Kamlesh Guleria
DNA and Cell Biology Reports.2025; 6(1): 22. CrossRef
Oxaliplatin‑induced changes in splenic volume and liver fibrosis indices: retrospective analyses of colon cancer patients receiving adjuvant chemotherapy
Kadriye Bir Yücel, Atiye Cenay Karabörk Kilic, Osman Sütcüoglu, Ozan Yazıcı, Koray Kilic, Gözde Savaş, Aytug Uner, Nazan Günel, Ahmet Özet, Nuriye Özdemir
Journal of Chemotherapy.2024; 36(3): 249. CrossRef
Effects of methanolic leaf extract and fractions of Irvingia gabonensis on hematological parameters in Wistar rats with splenomegaly
Fidelia Okoben, InnocentMary Ejiofor, Ikechukwu Mbagwu, Daniel Ajaghaku, Fredrick Anowi
Sciences of Pharmacy.2024; 3(1): 11. CrossRef
Clinical and genetic factors involved in Porto-sinusoidal vascular disorder after oxaliplatin exposure
A. Puente, J.I. Fortea, C. Del Pozo, M. Serrano, M. Alonso-Peña, A. Giráldez, L. Tellez, J. Martinez, M. Magaz, L. Ibañez, J. Garcia, E. Llop, C. Alvarez-Navascues, M. Romero, E. Rodriguez, M.T. Arias Loste, A. Antón, V. Echavarria, C. López, A. Albillos,
Digestive and Liver Disease.2024; 56(10): 1721. CrossRef
The “appearing” and “disappearing” ascites in the treatment of colorectal cancer: a case report
Hong-Ming Cui, Xin-Peng Shu, Zheng-Qiang Wei, Xing-Ye Wu
Frontiers in Oncology.2024;[Epub] CrossRef
A contrast-enhanced CT-based whole-spleen radiomics signature for early prediction of oxaliplatin-related thrombocytopenia in patients with gastrointestinal malignancies: a retrospective study
Yuhong Dai, Yiqi Cheng, Ziling Zhou, Zhen Li, Yan Luo, Hong Qiu
PeerJ.2023; 11: e16230. CrossRef
Natural Language Processing of Large-Scale Structured Radiology Reports to Identify Oncologic Patients With or Without Splenomegaly Over a 10-Year Period
Simon Sun, Kaelan Lupton, Karen Batch, Huy Nguyen, Lior Gazit, Natalie Gangai, Jessica Cho, Kevin Nicholas, Farhana Zulkernine, Varadan Sevilimedu, Amber Simpson, Richard K. G. Do
JCO Clinical Cancer Informatics.2022;[Epub] CrossRef
Model establishment and microarray analysis of mice with oxaliplatin‑induced hepatic sinusoidal obstruction syndrome
Chen Zhu, Xinwei Cheng, Ping Gao, Qianyan Gao, Ximin Wang, Dong Liu, Xiuhua Ren, Chengliang Zhang
Molecular Medicine Reports.2022;[Epub] CrossRef
Oxaliplatin-induced hepatic sinusoidal obstruction syndrome
Chen Zhu, Xiuhua Ren, Dong Liu, Chengliang Zhang
Toxicology.2021; 460: 152882. CrossRef
Association between single nucleotide polymorphisms (SNPs) of IL1, IL12, IL28 and TLR4 and symptoms of congenital cytomegalovirus infection
Dominika Jedlińska-Pijanowska, Beata Kasztelewicz, Justyna Czech-Kowalska, Maciej Jaworski, Klaudia Charusta-Sienkiewicz, Anna Dobrzańska, Michael Nevels
PLOS ONE.2020; 15(5): e0233096. CrossRef
Oxaliplatin-induced increase in splenic volume: experiences from multicenter study in Japan
Ryo Ohta, Takeshi Yamada, Keisuke Hara, Takuma Iwai, Kohji Tanakaya, Keiichiro Ishibashi, Kazuhiko Yoshimatsu, Chihiro Kosugi, Masahiro Tsubaki, Hideo Nakajima, Masatoshi Oya, Hiroshi Yoshida, Keiji Koda, Hideyuki Ishida
International Journal of Clinical Oncology.2020; 25(12): 2075. CrossRef
Oxaliplatin-induced haematological toxicity and splenomegaly in mice
Justin G. Lees, Daniel White, Brooke A. Keating, Mallory E. Barkl-Luke, Preet G. S. Makker, David Goldstein, Gila Moalem-Taylor, Senthilnathan Palaniyandi
PLOS ONE.2020; 15(9): e0238164. CrossRef
Olive Oil‐Based Ultrafine Theranostic Photo Nanoemulsions: A Versatile Tumor Maneuvering Nanoplatform for Precise Controlled Drug Release in Tumor and Complete Tumor Eradication Mediated by Photo‐Chemotherapy
N. Sanoj Rejinold, Kondareddy Cherukula, Jong Hoon Ha, In‐Kyu Park, Yeu‐Chun Kim
Advanced Therapeutics.2019;[Epub] CrossRef
Protective effect of Korean red ginseng on oxaliplatin-mediated splenomegaly in colon cancer
Jeonghyun Kang, Joon Seong Park, Sung Gwe Ahn, Jin Hong Lim, Seung Hyuk Baik, Dong Sup Yoon, Kang Young Lee, Joon Jeong
Annals of Surgical Treatment and Research.2018; 95(3): 161. CrossRef
Automatized spleen segmentation in non-contrast-enhanced MR volume data using subject-specific shape priors
Oliver Gloger, Klaus Tönnies, Robin Bülow, Henry Völzke
Physics in Medicine & Biology.2017; 62(14): 5861. CrossRef
UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer
Chunlei Xu, Xushan Tang, Yanli Qu, Saifuding Keyoumu, Ning Zhou, Yong Tang
Cancer Chemotherapy and Pharmacology.2016; 78(1): 119. CrossRef

13,425 View
160 Download
19 Web of Science
17 Crossref

Efficacy and Safety of Oxaliplatin, 5-Fluorouracil, and Folinic Acid Combination Chemotherapy as First-Line Treatment in Metastatic or Recurrent Gastric Cancer: Han Jo Kim, Jun Young Eun, Young Woo Jeon, Jina Yun, Kyoung Ha Kim, Se Hyung Kim, Hyun Jung Kim, Sang-Cheol Lee, Sang Byung Bae, Chan Kyu Kim, Nam Su Lee, Kyu Taek Lee, Seong-Kyu Park, Jong-Ho Won, Dae Sik Hong, Hee Sook Park; Cancer Res Treat. 2011;43(3):154-159. Published online September 30, 2011; DOI: https://doi.org/10.4143/crt.2011.43.3.154

Abstract PDF PubReader ePub

PURPOSE
We retrospectively determined the efficacy and safety of the combination of oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) as first-line chemotherapy for patients with metastatic or recurrent gastric cancer.
MATERIALS AND METHODS
Between January 2006 and August 2009, 39 patients with histologically-confirmed, metastatic or recurrent gastric cancer underwent chemotherapy, and the results were retrospectively investigated. The chemotherapy regimen consisted of oxaliplatin (100 mg/m2) and FA (200 mg/m2; 2-hour infusion), then 5-FU (2,400 mg/m2; 46-hour continuous infusion) every 2 weeks.
RESULTS
Thirty-nine patients received a total of 210 treatment cycles. The median number of cycles was 6 (range, 1 to 16). Of the 32 evaluable patients, zero patients achieved a complete response and 11 patients achieved a partial response (response rate, 28.2%). The median time-to-progression and overall survival were 4.3 months (95% confidence interval [CI], 2.0 to 6.5 months) and 9.8 months (95% CI, 3.5 to 16.0 months), respectively. The main hematologic toxicity was anemia, which was observed in 119 cycles (56.7%). Grade 3/4 neutropenia was observed in 32 cycles (15.2%). The main non-hematologic toxicity was constipation, which was observed in 91 cycles (46.2%). Peripheral neuropathy occurred in 71 cycles (33.8%); all cases were grade 1 or 2. No treatment-related deaths were reported.
CONCLUSION
This study showed that combination chemotherapy with oxaliplatin, 5-FU, and FA is an active and well-tolerated regimen as first-line treatment in patients with metastatic or recurrent gastric cancer.

Citations

Citations to this article as recorded by

Post-Marketing Surveillance of a generic Oxaliplatin (AlvoxalⓇ) in Iranian Patients with Cancer
Farhad Shahi, Mojtaba Gorji, Mehrdad Payandeh, Hamid Rezvani, Mohammad Vaezi, Sharareh Seifi, Alireza Baari, Reza Khalili-Dizaji, Seyed Mehdi Hashemi, Saeid Salimi, Hosein Kamranzadeh, Babak Shazad, Sina Salari, Davoud Oulad Dameshghi, Mehdi Sarkheil, Meh
Current Therapeutic Research.2022; 96: 100657. CrossRef
Quantitative proteomic analysis of oxaliplatin induced peripheral neurotoxicity
Linlin Yang, Hua Wang, Wanting Lu, Gangqi Yang, Zian Lin, Ruibing Chen, Hongyan Li
Journal of Proteomics.2022; 266: 104682. CrossRef
Current therapeutic options for gastric adenocarcinoma
C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
Saudi Journal of Biological Sciences.2021; 28(9): 5371. CrossRef
Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer
H Liu, J Lu, Y Hua, P Zhang, Z Liang, L Ruan, C Lian, H Shi, K Chen, Z Tu
Cell Death & Disease.2015; 6(1): e1595. CrossRef
Oxaliplatin induced-neuropathy in digestive tumors
María Sereno, Gerardo Gutiérrez-Gutiérrez, César Gómez-Raposo, Miriam López-Gómez, Maria Merino-Salvador, Francisco Zambrana Tébar, Cristina Rodriguez-Antona, Enrique Casado
Critical Reviews in Oncology/Hematology.2014; 89(1): 166. CrossRef
Effect of doxorubicin, oxaliplatin, and methotrexate administration on the transcriptional activity ofBCL-2family gene members in stomach cancer cells
Dimitra Florou, Christos Patsis, Alexandros Ardavanis, Andreas Scorilas
Cancer Biology & Therapy.2013; 14(7): 587. CrossRef
The kallikrein-related peptidase 13 (KLK13) gene is substantially up-regulated after exposure of gastric cancer cells to antineoplastic agents
Dimitra Florou, Konstantinos Mavridis, Andreas Scorilas
Tumor Biology.2012; 33(6): 2069. CrossRef

10,863 View
59 Download
7 Crossref

Phase II Clinical Trial of Genexol(R) (Paclitaxel) and Carboplatin for Patients with Advanced Non-small Cell Lung Cancer: Han Jo Kim, Kyoung Ha Kim, Jina Yun, Se Hyung Kim, Hyun Jung Kim, Sang-Cheol Lee, Sang Byung Bae, Chan Kyu Kim, Nam Su Lee, Kyu Taek Lee, Do-Jin Kim, Seong-Kyu Park, Jong-Ho Won, Dae Sik Hong, Hee Sook Park; Cancer Res Treat. 2011;43(1):19-23. Published online March 31, 2011; DOI: https://doi.org/10.4143/crt.2011.43.1.19

Abstract PDF PubReader ePub

PURPOSE
This phase II clinical trial was conducted to evaluate the activity and safety of a combination treatment of paclitaxel (Genexol(R)) plus carboplatin in patients with advanced non-small cell lung cancer.
MATERIALS AND METHODS
Chemotherapy-naive patients having histologically confirmed advanced or metastatic non-small cell lung cancer were enrolled. Genexol(R) was administered at 225 mg/m2 intravenous (IV) infusion over 3 hours, followed by carboplatin (area under the concentration-time curve=6) IV on day 1 every 3 weeks.
RESULTS
Twenty-eight patients were enrolled between January 2003 and January 2005. A total of 110 cycles of chemotherapy were given. The median number of chemotherapy cycles was 4. A total of 25 study patients were evaluable. On an intent-to-treat basis, there were ten partial responses (response rate 35.7%). The median time-to-progression was 3.2 months (95% confidence interval [CI], 1.5 to 4.9) and the median overall survival was 8.2 months (95% CI, 4.1 to 12.3). The main hematologic grade 3/4 toxicity was neutropenia, which was observed in 14 (50.0%) patients. The main non-hematologic toxicity was peripheral neuropathy, which was observed in 12 patients (42.9%). Grade 3/4 neuropathy occurred in 8 patients (28.6%) and three patients discontinued treatment because of neuropathy.
CONCLUSION
In this trial, the combination of Genexol(R) and carboplatin showed significant activity as first line treatment for patients with advanced or metastatic non-small cell lung cancer. However, a modest dose reduction of Genexol(R) is needed due to sensory neuropathy.

Citations

Citations to this article as recorded by

Therapeutic Nanoparticles: Advantages and Toxicity
Dr. Lata Ramrakhiani
Indian Journal of Environment Engineering.2022; 2(1): 19. CrossRef
Engineering Chimeric Receptors To Investigate the Size- and Rigidity-Dependent Interaction of PEGylated Nanoparticles with Cells
Wei-Chiao Huang, Pierre-Alain Burnouf, Yu-Cheng Su, Bing-Mae Chen, Kuo-Hsiang Chuang, Chia-Wei Lee, Pei-Kuen Wei, Tian-Lu Cheng, Steve R. Roffler
ACS Nano.2016; 10(1): 648. CrossRef
Nanotechnology applications in thoracic surgery
Sophie C. Hofferberth, Mark W. Grinstaff, Yolonda L. Colson
European Journal of Cardio-Thoracic Surgery.2016; 50(1): 6. CrossRef
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
Nazila Kamaly, Basit Yameen, Jun Wu, Omid C. Farokhzad
Chemical Reviews.2016; 116(4): 2602. CrossRef
Novel Water-Borne Polyurethane Nanomicelles for Cancer Chemotherapy: Higher Efficiency of Folate Receptors Than TRAIL Receptors in a Cancerous Balb/C Mouse Model
Elham Ajorlou, Ahmad Yari Khosroushahi, Hamid Yeganeh
Pharmaceutical Research.2016; 33(6): 1426. CrossRef
Reinvention of chemotherapy
Tu Nguyen-Ngoc, Eric Raymond
Current Opinion in Oncology.2015; 27(3): 232. CrossRef
Lung Cancer Nanomedicine: Potentials and Pitfalls
Deniz Ali Bölükbas, Silke Meiners
Nanomedicine.2015; 10(21): 3203. CrossRef
Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
Susana Patricia Egusquiaguirre, Manuela Igartua, Rosa María Hernández, José Luis Pedraz
Clinical and Translational Oncology.2012; 14(2): 83. CrossRef
Novel water-soluble polyurethane nanomicelles for cancer chemotherapy: physicochemical characterization and cellular activities
Ahmad Yari Khosroushahi, Hossein Naderi-Manesh, Hamid Yeganeh, Jaleh Barar, Yadollah Omidi
Journal of Nanobiotechnology.2012;[Epub] CrossRef
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Twan Lammers, Fabian Kiessling, Wim E. Hennink, Gert Storm
Journal of Controlled Release.2012; 161(2): 175. CrossRef

11,319 View
69 Download
10 Crossref

Case Report

A Case of Desmoplastic Small Round Cell Tumor Diagnosed in a Young Female Patient: Ji-Won Kim, Jin Hyun Park, Hyeon Jin Cho, Ji-Hyun Kwon, Youngil Koh, Su-Jung Kim, Se Hyung Kim, Se-Hoon Lee, Seock-Ah Im, Yong-Tae Kim, Woo Ho Kim; Cancer Res Treat. 2009;41(4):233-236. Published online December 31, 2009; DOI: https://doi.org/10.4143/crt.2009.41.4.233

Abstract PDF PubReader ePub

Desmoplastic small round cell tumor is a very rare malignancy. We report the case of a 26-year-old woman who suffered from dyspepsia and abdominal pain for 2 months. We performed an endoscopic biopsy of the duodenal mass and diagnosed her disease as desmoplastic small round cell tumor using immunohistochemical staining, fluorescence in situ hybridization, and reverse transcriptase polymerase chain reaction. Because the mass invaded the pancreas and superior mesenteric vein as well as duodenum and the disease was disseminated to liver and peritoneum, she received palliative chemotherapy using vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide. The maximal response to chemotherapy was stable disease. The patient expired 9 months after diagnosis.

Citations

Citations to this article as recorded by

Intra-Abdominal Desmoplastic Small Round Cell Tumor: Current Treatment Options and Perspectives
Guixia Wei, Xinyao Shu, Yuwen Zhou, Xia Liu, Xiaorong Chen, Meng Qiu
Frontiers in Oncology.2021;[Epub] CrossRef
A Case Report of Abdominal Desmoplastic Small Round Cell Tumor in a Young Tunisian Woman
Karim Nacef, Mohamed Ali Chaouch, Rym Bouriga, Mohamed Ben Khalifa, Asma Chaouch, Mossab Ghannouchi, Moez Boudokhane
Journal of Gastrointestinal Cancer.2019; 50(3): 568. CrossRef
Primary desmoplastic small-round-cell tumor of the ovary
Ahmed Atef, Khaled Gaballa, Mohammad Zuhdy, Khalid Atallah, Wagdi Elkashef, Shadi Awny, Basma Gadelhak, Basel Refky
Journal of the Egyptian National Cancer Institute.2019;[Epub] CrossRef
Tumor intraabdominal desmoplásico de células pequeñas y redondas
Andrés Alejandro Briseño-Hernández, Deissy Roxana Quezada-López, Lilia Edith Corona-Cobián, Agar Castañeda-Chávez, Alfonso Tonatiuh Duarte-Ojeda, Michel Dassaejv Macías-Amezcua
Cirugía y Cirujanos.2015; 83(3): 243. CrossRef
Intra-abdominal desmoplastic small round cell tumour
Andrés Alejandro Briseño-Hernández, Deissy Roxana Quezada-López, Lilia Edith Corona-Cobián, Agar Castañeda-Chávez, Alfonso Tonatiuh Duarte-Ojeda, Michel Dassaejv Macías-Amezcua
Cirugía y Cirujanos (English Edition).2015; 83(3): 243. CrossRef
Primary desmoplastic small round cell tumor of the duodenum
Qi Liu, Nan Liu, DeXing Chen
European Journal of Medical Research.2014;[Epub] CrossRef
Tumor desmoplásico de células pequeñas y redondas. Diagnóstico y tratamiento
Izaskun Markinez Gordobil, Inmaculada Ruiz, Raúl Jiménez, Eloisa Villarreal, Aintzane Lizarazu, Nerea Borda, Xabier Arteaga, Miguel Ángel Medrano, Esther Guisasola, Adolfo Beguiristain, José María E. Navascués
Gaceta Médica de Bilbao.2012; 109(3): 101. CrossRef
Desmoplastic small round cell tumor of the abdomen: A case report and literature review of therapeutic options
Hafida Benhammane, Leila Chbani, Abdelmalek Ousadden, Ouadii Mouquit, Siham Tizniti, Afaf Riffi Amarti, Nouafal Mellas, Omar El Mesbahi
Health.2012; 04(04): 207. CrossRef
Analysis of Prognostic Factors of Pediatric-Type Sarcomas in Adult Patients
Hee Kyung Ahn, Ji Eun Uhm, Jeeyun Lee, Do Hoon Lim, Sung Wook Seo, Ki-Sun Sung, Su Jin Lee, Duk Joo Lee, Kyung Kee Baek, Won-Seog Kim, Joon Oh Park
Oncology.2011; 80(1-2): 21. CrossRef

11,848 View
62 Download
9 Crossref

First
Prev
Page of 1
Next
Last

Search